Related Experiment Videos

Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an

J Mendelsohn1, H Masui, A Goldenberg

  • 1Memorial Sloan-Kettering Cancer Center, New York, NY.

Transactions of the Association of American Physicians
|January 1, 1987
PubMed

Insights

Monoclonal antibodies targeting the epidermal growth factor (EGF) receptor can halt cancer cell growth. This antibody-driven inhibition appears to stem from disrupting essential growth factor-dependent cellular processes.

Area of Science:

  • Cell biology
  • Immunology
  • Oncology

Background:

  • The epidermal growth factor (EGF) receptor plays a crucial role in cell proliferation and biochemical functions.
  • EGF receptor signaling is implicated in the growth of various tumor cells.
  • Monoclonal antibodies offer a potential therapeutic strategy by targeting specific cell surface receptors.

Purpose of the Study:

  • To investigate the effects of monoclonal antibodies against the EGF receptor on human cell functions.
  • To determine if these antibodies can inhibit the proliferation of EGF receptor-bearing tumor cells.
  • To elucidate the mechanisms underlying antibody-mediated antiproliferative activity.

Main Methods:

  • Utilizing cultured human cells, including those with EGF receptors.
  • Administering monoclonal antibodies specific to the EGF receptor.
  • Assessing the impact of antibody treatment on cell proliferation and biochemical functions.
  • Analyzing the effects on growth factor-dependent cellular processes.

Main Results:

  • Monoclonal antibodies binding to the EGF receptor effectively inhibited EGF-induced proliferation and biochemical functions in cultured human cells.
  • Treatment with anti-EGF receptor antibodies demonstrated a capacity to prevent the growth of certain tumor cells expressing the receptor.
  • The antiproliferative effects of the antibodies were linked to interference with growth factor-dependent pathways within the receptor-bearing cells.

Conclusions:

  • Monoclonal antibodies targeting the EGF receptor are potent inhibitors of EGF-mediated cellular activities.
  • These antibodies show promise as a therapeutic approach for inhibiting the growth of EGF receptor-dependent tumors.
  • The mechanism of action involves disrupting critical growth factor-dependent cellular processes, leading to antiproliferative effects.

Related Concept Videos